Compare CABA & MBUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | MBUU |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.7M | 541.4M |
| IPO Year | 2019 | 2013 |
| Metric | CABA | MBUU |
|---|---|---|
| Price | $3.25 | $26.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $14.50 | ★ $32.20 |
| AVG Volume (30 Days) | ★ 4.2M | 195.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $914,590,000.00 |
| Revenue This Year | N/A | $2.14 |
| Revenue Next Year | N/A | $12.78 |
| P/E Ratio | ★ N/A | $299.56 |
| Revenue Growth | N/A | ★ 13.25 |
| 52 Week Low | $1.44 | $23.84 |
| 52 Week High | $4.23 | $35.06 |
| Indicator | CABA | MBUU |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 38.33 |
| Support Level | $3.12 | $24.27 |
| Resistance Level | $3.34 | $29.81 |
| Average True Range (ATR) | 0.22 | 1.22 |
| MACD | 0.02 | -0.37 |
| Stochastic Oscillator | 68.32 | 6.77 |
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Most recently, in 2026, it tied up with Saxdor Yachts, focused on adventure dayboats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.